{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:05:09Z","timestamp":1771243509824,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,16]]},"DOI":"10.7759\/cureus.103701","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:11:33Z","timestamp":1771240293000},"source":"Crossref","is-referenced-by-count":0,"title":["Restage Transurethral Resection in the Evaluation of T1 High-Grade Bladder Tumor"],"prefix":"10.7759","author":[{"given":"Shibbir","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahabub","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanzila","family":"Binte Jafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rejwane Mahmud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Ehsan Mahmud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayeedur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ove","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S M","family":"Anwarul Kabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.03.40","article-title":"Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy","volume":"9","author":"Piszczek R","year":"2020","unstructured":"Piszczek R, Krajewski W, Ma\u0142kiewicz B, et al.. Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy. Transl Androl Urol. 2020, 9:1338-44. 10.21037\/tau.2020.03.40","journal-title":"Transl Androl Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190362","article-title":"Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1\/2-AP-1 signaling pathway","volume":"39","author":"Tsai TF","year":"2019","unstructured":"Tsai TF, Lin JF, Lin YC, et al.. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1\/2-AP-1 signaling pathway. Biosci Rep. 2019, 39:10.1042\/BSR20190362","journal-title":"Biosci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194775","article-title":"The impact of meat intake on bladder cancer incidence: is it really a relevant risk?","volume":"14","author":"Aveta A","year":"2022","unstructured":"Aveta A, Cacciapuoti C, Barone B, et al.. The impact of meat intake on bladder cancer incidence: is it really a relevant risk?. Cancers (Basel). 2022, 14:10.3390\/cancers14194775","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Rumgay H, Li M, et al.. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health. 2023, 13:04109. 10.7189\/jogh.13.04109","journal-title":"J Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel RL","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018, 68:7-30. 10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, et al.. Epidemiology of bladder cancer. Med Sci (Basel). 2020, 8:10.3390\/medsci8010015","journal-title":"Med Sci (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours","volume":"70","author":"Humphrey PA","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, et al.. The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours. Eur Urol. 2016, 70:106-19. 10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles T","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al.. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:244-58. 10.1016\/j.annonc.2021.11.012","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2017.0424","article-title":"Comparative differences between T1a\/b and T1e\/m as substages in T1 urothelial carcinoma of the bladder","volume":"44","author":"Turan T","year":"2018","unstructured":"Turan T, Efilo\u011flu \u00d6, G\u00fcnaydin B, et al.. Comparative differences between T1a\/b and T1e\/m as substages in T1 urothelial carcinoma of the bladder. Int Braz J Urol. 2018, 44:267-72. 10.1590\/S1677-5538.IBJU.2017.0424","journal-title":"Int Braz J Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner GP","year":"2018","unstructured":"Paner GP, Stadler WM, Hansel DE, et al.. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018, 73:560-9. 10.1016\/j.eururo.2017.12.018","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_351_18","article-title":"Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India","volume":"56","author":"Prakash G","year":"2019","unstructured":"Prakash G, Pal M, Odaiyappan K, et al.. Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian J Cancer. 2019, 56:54-8. 10.4103\/ijc.IJC_351_18","journal-title":"Indian J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester RJ","year":"2004","unstructured":"Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004, 171:2186-90, quiz 2435. 10.1097\/01.ju.0000125486.92260.b2","journal-title":"J Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/end.2010.0319","article-title":"Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer","volume":"24","author":"Ali MH","year":"2010","unstructured":"Ali MH, Ismail IY, Eltobgy A, Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer. J Endourol. 2010, 24:2047-50. 10.1089\/end.2010.0319","journal-title":"J Endourol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2015.56.6.429","article-title":"The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: results of a prospective study","volume":"56","author":"Shim JS","year":"2015","unstructured":"Shim JS, Choi H, Noh TI, et al.. The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: results of a prospective study. Korean J Urol. 2015, 56:429-34. 10.4111\/kju.2015.56.6.429","journal-title":"Korean J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1310-0","article-title":"Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer","volume":"16","author":"Zapa\u0142a P","year":"2018","unstructured":"Zapa\u0142a P, Dybowski B, Poletajew S, et al.. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J Surg Oncol. 2018, 16:6. 10.1186\/s12957-018-1310-0","journal-title":"World J Surg Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik RT","year":"2010","unstructured":"Divrik RT, Sahin AF, Yildirim U, et al.. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010, 58:185-90. 10.1016\/j.eururo.2010.03.007","journal-title":"Eur Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik RT","year":"2006","unstructured":"Divrik RT, Yildirim U, Zorlu F. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006, 175:1641-1644. 10.1016\/S0022-5347(05)01002-5","journal-title":"J Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli A","year":"2018","unstructured":"Naselli A, Hurle R, Paparella S, et al.. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018, 4:558-67. 10.1016\/j.euf.2016.12.011","journal-title":"Eur Urol Focus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.06.042","article-title":"Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?","volume":"35","author":"Audenet F","year":"2017","unstructured":"Audenet F, Retinger C, Chien C, et al.. Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. Urol Oncol. 2017, 35:603.e1-5. 10.1016\/j.urolonc.2017.06.042","journal-title":"Urol Oncol"},{"key":"ref20","article-title":"Sample size calculations in clinical research","volume":"31","author":"Chow S","year":"2008","unstructured":"Chow S, Shao J, Wang H, et al.. Sample size calculations in clinical research. Chapman. 2008, 31:180-191.","journal-title":"Chapman"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.04.009","article-title":"Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer","volume":"39","author":"Tan YG","year":"2021","unstructured":"Tan YG, Quek SZ, Huang HH, et al.. Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer. Urol Oncol. 2021, 39:829.e9-829.e17. 10.1016\/j.urolonc.2021.04.009","journal-title":"Urol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: all you need to know","volume":"14","author":"Halaseh SA","year":"2022","unstructured":"Halaseh SA, Halaseh S, Alali Y, et al.. A review of the etiology and epidemiology of bladder cancer: all you need to know. Cureus. 2022, 14:e27330. 10.7759\/cureus.27330","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly","volume":"27","author":"Shariat SF","year":"2009","unstructured":"Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009, 27:653-67. 10.1016\/j.urolonc.2009.07.020","journal-title":"Urol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1315","article-title":"Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction","volume":"6","author":"Taylor JA 3rd","year":"2009","unstructured":"Taylor JA 3rd, Kuchel GA. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol. 2009, 6:135-44. 10.1038\/ncpuro1315","journal-title":"Nat Clin Pract Urol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202311_34320","article-title":"Young population bladder neoplasms","volume":"27","author":"\u00c7ivi \u00c7etin K","year":"2023","unstructured":"\u00c7ivi \u00c7etin K, \u00d6ner S, et al.. Young population bladder neoplasms. Eur Rev Med Pharmacol Sci. 2023, 27:10454-61. 10.26355\/eurrev_202311_34320","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231152322","article-title":"Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004-2015","volume":"30","author":"Lin W","year":"2023","unstructured":"Lin W, Pan X, Zhang C, et al.. Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004-2015. Cancer Control. 2023, 30:10732748231152322. 10.1177\/10732748231152322","journal-title":"Cancer Control"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-024-01950-w","article-title":"Comparative analysis of clinicopathologic characteristics and outcomes of urothelial bladder cancer between young and older adults-experience from a tertiary care center","volume":"15","author":"Singh P","year":"2024","unstructured":"Singh P, Sachan A, Nayak B, et al.. Comparative analysis of clinicopathologic characteristics and outcomes of urothelial bladder cancer between young and older adults-experience from a tertiary care center. Indian J Surg Oncol. 2024, 15:563-71. 10.1007\/s13193-024-01950-w","journal-title":"Indian J Surg Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/iju.IJU_218_17","article-title":"Utility of restage transurethral resection of bladder tumor","volume":"34","author":"Manoharan V","year":"2018","unstructured":"Manoharan V, Mavuduru RS, Kumar S, et al.. Utility of restage transurethral resection of bladder tumor. Indian J Urol. 2018, 34:273-7. 10.4103\/iju.IJU_218_17","journal-title":"Indian J Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu A","year":"2020","unstructured":"Eroglu A, Ekin RG, Koc G, Divrik RT. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol. 2020, 25:698-704. 10.1007\/s10147-019-01581-0","journal-title":"Int J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3453808","article-title":"Urinary bladder cancer in Egypt: are there gender differences in its histopathological presentation?","volume":"2018","author":"Kyritsi F","year":"2018","unstructured":"Kyritsi F, Loffredo CA, Zheng YL, et al.. Urinary bladder cancer in Egypt: are there gender differences in its histopathological presentation?. Adv Urol. 2018, 2018:3453808. 10.1155\/2018\/3453808","journal-title":"Adv Urol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1326627","article-title":"Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes","volume":"14","author":"Zhu S","year":"2023","unstructured":"Zhu S, Zhao H. Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes. Front Pharmacol. 2023, 14:1326627. 10.3389\/fphar.2023.1326627","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2023.2166103","article-title":"The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy","volume":"57","author":"Secher MS","year":"2023","unstructured":"Secher MS, Hyldgaard J, Jensen JB. The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy. Scand J Urol. 2023, 57:10-4. 10.1080\/21681805.2023.2166103","journal-title":"Scand J Urol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234100","article-title":"Sex disparities in bladder cancer diagnosis and treatment","volume":"16","author":"Pignot G","year":"2024","unstructured":"Pignot G, Barth\u00e9l\u00e9my P, Borchiellini D. Sex disparities in bladder cancer diagnosis and treatment. Cancers (Basel). 2024, 16:10.3390\/cancers16234100","journal-title":"Cancers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.140990","article-title":"Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer","volume":"6","author":"Gill TS","year":"2014","unstructured":"Gill TS, Das RK, Basu S, et al.. Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer. Urol Ann. 2014, 6:305-8. 10.4103\/0974-7796.140990","journal-title":"Urol Ann"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.777","article-title":"Update on the management of non-muscle invasive bladder cancer","volume":"4","author":"Aldousari S","year":"2010","unstructured":"Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010, 4:56-64. 10.5489\/cuaj.777","journal-title":"Can Urol Assoc J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr HW","year":"1999","unstructured":"Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999, 162:74-6. 10.1097\/00005392-199907000-00018","journal-title":"J Urol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi M","year":"2002","unstructured":"Brausi M, Collette L, Kurth K, et al.. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002, 41:523-531. 10.1016\/S0302-2838(02)00068-4","journal-title":"Eur Urol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.788568","article-title":"Risk stratification for the rate and location of residual bladder tumor for the decision of re-transurethral resection of bladder tumor","volume":"12","author":"Fan J","year":"2022","unstructured":"Fan J, Zhang X, Fan J, et al.. Risk stratification for the rate and location of residual bladder tumor for the decision of re-transurethral resection of bladder tumor. Front Oncol. 2022, 12:788568. 10.3389\/fonc.2022.788568","journal-title":"Front Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1159\/000075961","article-title":"Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists","volume":"72","author":"Zurkirchen MA","year":"2004","unstructured":"Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int. 2004, 72:99-102. 10.1159\/000075961","journal-title":"Urol Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00465","article-title":"Is repeat transurethral resection always needed in high-grade T1 bladder cancer?","volume":"9","author":"Cal\u00f2 B","year":"2019","unstructured":"Cal\u00f2 B, Chirico M, Fortunato F, et al.. Is repeat transurethral resection always needed in high-grade T1 bladder cancer?. Front Oncol. 2019, 9:465. 10.3389\/fonc.2019.00465","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461625-restage-transurethral-resection-in-the-evaluation-of-t1-high-grade-bladder-tumor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:11:34Z","timestamp":1771240294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461625-restage-transurethral-resection-in-the-evaluation-of-t1-high-grade-bladder-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.103701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}